- Home
- LYEL vs MRVI Comparison
LYEL vs MRVI Comparison
Compare LYEL & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYEL | MRVI |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.1M | 472.8M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LYEL | MRVI |
|---|---|---|
| Price | $22.46 | $3.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $27.25 | $4.00 |
| AVG Volume (30 Days) | 101.0K | ★ 1.2M |
| Earning Date | 06-15-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | N/A | ★ N/A |
| Revenue | $36,000.00 | ★ $185,743,000.00 |
| Revenue This Year | N/A | $11.80 |
| Revenue Next Year | N/A | $7.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $1.67 |
| 52 Week High | $45.00 | $4.11 |
Technical Indicators
Market Signals| Indicator | LYEL | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 42.37 | 41.64 |
| Support Level | $21.27 | $2.88 |
| Resistance Level | $27.30 | $3.99 |
| Average True Range (ATR) | 1.92 | 0.21 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 17.91 | 16.48 |
Price Performance
Historical ComparisonAbout LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.